Skip to main content
Caplight Logo









PrognomiQ

PrognomiQ

Private
San Mateo, CaliforniaHealthcare & Life Scienceshttps://prognomiq.com/

Last Round

Series D

Nov 5, 2024

Total Funding Raised

$135M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

PrognomiQ is a biotechnology company that develops multi-omics diagnostic test products for the early detection and treatment of cancer and other complex diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

proteomicslaboratory developed testLDTliquid biopsyearly cancer detectionlung cancer screeningmulti-omicsbiomarker discoveryblood-based testcancer diagnosticsprecision oncologyclinical diagnosticsdiagnostic testbiotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

PrognomiQ Comparables

Compare PrognomiQ with similar companies based on industry and business-model similarity.

PrognomiQ comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Delfi Diagnostics
86%
Biodesix Inc
81%
Harbinger Health
80%

PrognomiQ Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DNov 5, 2024
Series CMar 15, 2022
Series BSep 15, 2020

Key People

Founding team and executive leadership

Philip Ma

Chief Executive Officer, President, Founder

Founding Team

PrognomiQ Investors

Notable investors and investment history

PrognomiQ investors
InvestorRounds
Maverick VenturesSeries C, Series B
Fidelity Management & Research CompanySeries C, Series B
Catalio Capital ManagementSeries C, Series D
Invus OpportunitiesSeries C
T. Rowe PriceSeries C, Series B
aMoonSeries C, Series D, Series B
Wing Venture CapitalSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 23, 2026

    Monthly visitors grew 40% MoM, reaching 4.1K.

  • Nov 18, 2025

    Launched ProVue Lung, a blood test for early lung cancer detection.

PrognomiQ Filings

Explore SEC and related filing metadata, where available.

PrognomiQ filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about PrognomiQ's valuation, stock price, and market status.

Is PrognomiQ a public or private company?

PrognomiQ is a private company.

What is the current stock price of PrognomiQ?

PrognomiQ is a private company with no public stock price. No recent secondary market data is available.

How much is PrognomiQ worth (valuation)?

Valuation information for PrognomiQ is not publicly available.

Can I buy PrognomiQ stock?

PrognomiQ shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was PrognomiQ's last funding round?

PrognomiQ's most recent funding round was Series D on November 5, 2024.

Who are the main investors in PrognomiQ?

Key investors in PrognomiQ include aMoon.

Will PrognomiQ IPO soon?

No public IPO plans have been announced for PrognomiQ.

How can I track PrognomiQ secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor PrognomiQ's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Mateo, California
Employee Range36
Year Founded2020
Last FundingNov 5, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?